ReviewTherapeutic advances in hematology2014

Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.

Amin Aalipour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.